{
    "nctId": "NCT00149214",
    "briefTitle": "Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens",
    "officialTitle": "A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 257,
    "primaryOutcomeMeasure": "Number of Participants With a Pathological Complete Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed diagnosis of primary early breast cancer, tumor size greater than or equal to 2 centimeters (cm), of Stages T2-T4/N0-2.\n* Performance status 0-2 Eastern Cooperative Oncology Group (ECOG).\n* Adequate organ function (bone marrow, hepatic, renal, cardiac).\n\nExclusion Criteria:\n\n* Prior anthracyclines as part of prior anticancer therapy.\n* Concurrent antitumor therapy.\n* Second primary malignancy.\n* Serious concomitant systemic disorder.\n* Pre-existing sensorial or motor neuropathy\n\n  * Grade 1.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}